Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 18

1927P - AL2846 in patients (pts) with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) previously treated with tyrosine kinase inhibitors (TKI): Preliminary clinical results from the phase Ib study

Date

14 Sep 2024

Session

Poster session 18

Topics

Tumour Site

Thyroid Cancer

Presenters

Feng Shi

Citation

Annals of Oncology (2024) 35 (suppl_2): S1122-S1128. 10.1016/annonc/annonc1614

Authors

F. Shi1, W. Chai1, H. Yang2, W. cao3, S. Zhang4, Z. chen5, W. Ouyang6, Y. cui7

Author affiliations

  • 1 Nuclear Medicine, Hunan Cancer Hospital, 410013 - Changsha/CN
  • 2 Nuclear Medicine, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, 450008 - Zhengzhou/CN
  • 3 Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology/ Cancer Center Union Hospital, 430022 - Wuhan/CN
  • 4 Otolaryngology Head And Neck Surgery, The first affiliated hospital of Xi'an Jiaotong university, 710061 - Xi'an City/CN
  • 5 Nuclear Medicine, Jiangxi Provincial Cancer Hospital, 330029 - Nanchang/CN
  • 6 Nuclear Medicine, Zhujiang Hospital of Southern Medical University, 501280 - Guangzhou/CN
  • 7 Nuclear Medicine, Cancer Hospital Affiliated to Harbin Medical University, 150084 - Harbin/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1927P

Background

Approximately 15% of metastatic DTC will become RR, with a substantial impact on its prognosis. Although the majority of pts with RR-DTC initially achieve disease control with TKI, most will eventually develop treatment resistance and disease progression. AL2846, a multikinase inhibitor, mediate tumor growth and angiogenesis inluding VEGFR, AxL, c-MET, may lead to improved efficacy of pts with RR-DTC treated with prior TKI.

Methods

This multi-center, open-label, phase Ib study enrolled RR-DTC pts treaed with prior TKI therapy. Eligible pts received oral 90mg or 120mg of AL2846 capsules, once daily. The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS) and safety.

Results

From 16 Feb 2023 to 31 Mar 2024, total 28 pts (90mg, n=17; 120mg, n=11) were enrolled in this study, with 27 pts (96%) remaining on treatment. 20 pts were papillary carcinoma, 8 pts were follicular carcinoma. All pts had progressed following 1 or 2 prior VEGFR-targeted therapy, about 22% patients received 2 lines of prior therapy. Among the 28 pts, 21 were efficacy evaluable, 7 have not reached the first evaluation. 2 pts achieved partial response (PR), while 19 pts had stable disease (SD) at best response, 11 pts had SD more than 16 weeks. DCR was 100% (21/21). The most common (>20%) treatment-emergent adverse events (TEAE) included AST/ALT increased, hypocalcemia, hypertension, elevated lactic dehydrogenase (LDH), hypercholesterolemia, hand-foot syndrome (HFS). TEAE ≥ grade 3 occurred in 5% of pts, only 1 patient had serious adverse event (SAE) of nephrotic syndrome. 4 pts led to dose reduction of AL2846 mainly due to HFS, proteinuria and oral mucositis. Interestingly, 1 patient achieved tumor shrinkage after dose-upregulation to 120mg during treatment, and was well tolerated.

Conclusions

AL2846 demonstrated a well-tolerated safety profile and a promising antitumor activity in previously TKI treated RR-DTC pts, which warrants further clinical evaluation.

Clinical trial identification

NCT05745363.

Editorial acknowledgement

Legal entity responsible for the study

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Funding

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.